|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0130 AUD | -7.14% |
|
-7.14% | -13.33% |
| 28/05 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 27/05 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 71.86L 49.61L 43.5L 40.1L 37.54L 70.39L 47Cr 4.82Cr 1.86Cr 23Cr 1.86Cr 1.82Cr 80Cr | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 99.58L 68.75L 60.28L 55.57L 52.02L 97.55L 65Cr 6.68Cr 2.58Cr 32Cr 2.58Cr 2.53Cr 111.15Cr | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/22/23 | Acrux : Application for quotation of securities - ACR | PU |
| 14/22/14 | Acrux : Application for quotation of securities - ACR | PU |
| 16/22/16 | Acrux : Application for quotation of securities - ACR | PU |
| 25/22/25 | Acrux : Updated Board Charter | PU |
| 25/22/25 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | -7.14% | ||
| 1 week | -7.14% | ||
| Current month | +8.33% | ||
| 1 month | +8.33% | ||
| 3 months | +18.18% | ||
| 6 months | -13.33% | ||
| Current year | -13.33% |
| 1 week | 0.01 | 0.02 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.14% | -7.14% | -18.75% | -69.77% | 49.61L | ||
| +0.85% | +0.96% | +12.24% | +78.85% | 4.74TCr | ||
| +0.79% | +2.83% | +52.57% | +106.39% | 3.55TCr | ||
| +2.08% | +4.18% | -2.06% | +45.32% | 1.23TCr | ||
| +1.23% | +2.77% | +12.69% | +91.34% | 1.16TCr | ||
| -2.10% | +0.38% | +36.72% | +126.29% | 888.1Cr | ||
| -0.49% | +2.87% | +22.00% | +43.53% | 720.73Cr | ||
| +1.37% | +2.75% | +54.59% | -8.50% | 691.07Cr | ||
| +1.18% | -0.49% | +24.36% | +222.65% | 644.5Cr | ||
| -3.83% | -0.76% | -35.52% | -3.58% | 494.11Cr | ||
| Average | -0.55% | +1.69% | +15.88% | +63.25% | 1.41TCr | |
| Weighted average by Cap. | +0.67% | +2.86% | +24.15% | +84.45% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 50.91L 35.15L 30.82L 28.41L 26.6L 49.87L 33Cr 3.41Cr 1.32Cr 16Cr 1.32Cr 1.29Cr 57Cr | 11.9L 8L 7L 7L 6L 11.66L 7.75Cr 79.82L 30.88L 3.83Cr 30.85L 30.18L 13Cr |
| Net income | -58L -40.05L -35.11L -32.37L -30.3L -56.82L -38Cr -3.89Cr -1.51Cr -19Cr -1.5Cr -1.47Cr -65Cr | -59.45L -41.05L -35.99L -33.18L -31.06L -58.24L -39Cr -3.99Cr -1.54Cr -19Cr -1.54Cr -1.51Cr -66Cr |
| Net Debt | 8L 5L 5L 4L 4L 7L 4.94Cr 50.91L 19.7L 2.44Cr 19.68L 19.25L 8.47Cr | 27.72L 19.14L 16.78L 15.47L 14.48L 27.16L 18Cr 1.86Cr 71.94L 8.92Cr 71.87L 70.3L 31Cr |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | A$0.0130 | -7.14% | 2,37,052 |
| 26/26/26 | A$0.0140 | +7.69% | 7,89,030 |
| 25/26/25 | A$0.0130 | -7.14% | 13,27,517 |
| 24/26/24 | A$0.0140 | +7.69% | 3,69,855 |
| 23/26/23 | A$0.0130 | -7.14% | 22,04,776 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















